A Phase 1 Clinical Trial of Personalized, Adoptive Cellular Immunotherapy Targeting Patient-specific Neoplastic Stem Cell Neoantigens (PACTN) in Patients With Myelodysplastic Syndromes (MDS)
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Myelodysplastic Syndromes
- Sponsor
- PersImmune, Inc
- Enrollment
- 12
- Locations
- 1
- Primary Endpoint
- Acute and subacute toxicities and AEs
- Last Updated
- 6 years ago
Overview
Brief Summary
This study will evaluate the safety of autologous T cells that have been immunized ex vivo with patient-specific MDS stem cell neoantigens in patients with MDS.
Detailed Description
PACTN is manufactured by a novel method to employ cancer-specific somatic variants (mutations) as a means to immunize autologous T lymphocytes to specifically kill cancer cells bearing the protein products of the mutations. The PACTN method is based on the premise that somatic DNA mutations that cause cancer often give rise to proteins with an altered amino acid sequence. Peptides derived from these proteins, if expressed in the context of MHC Class I or II may be perceived as "non-self" by the immune system; that is, they may be perceived as neoantigens (aka, neoepitopes). Such neoantigens could therefore serve as immunogenic targets for the development of patient-specific, personalized T cell mediated immunotherapy.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Confirmed diagnosis of MDS according to the French-American-British (FAB) criteria. Subjects with MDS must have intermediate, high, or very high risk IPSS-R scores and cytopenia of at least one lineage.
- •Relapsed/refractory disease, or inadequate response to at least 6 cycles of hypomethylating (HMA) therapy or subjects who decline HMA therapy. Subjects must not have received any MDS or AML directed therapy for \>28 days prior to receiving the study treatment.
- •Subjects who have opted not to undergo allogeneic hematopoietic stem cell transplantation or for whom no donor is available and who are not deemed eligible for high intensity chemotherapy.
- •Age \>18 year at the time of obtaining informed consent, male or female.
- •An Eastern Cooperative Oncology Grou (ECOG) performance status score of 0, 1, or
- •Adequate organ function.
- •Seronegative test for HIV-1/2 and hepatitis C antibodies (HCV), and a negative test for Hepatitis B antigen (HBsAg). If hepatitis C antibody test is positive, then the subject must be tested for the presence of antigen by RT-PCR and be HCV RNA negative.
- •Women of childbearing potential must have negative pregnancy test prior to initiating study treatment.
- •Life expectancy \>6 months at time of screening.
- •Ability to adhere to the protocol requirements and study visit schedule.
Exclusion Criteria
- •Subjects who anticipate use of other investigational or non-investigational agents for the treatment of MDS during the study period, aside from a stable dose of erythropoietin stimulating agent started \>8 weeks prior to screening for this study.
- •Subjects who have received investigational agents, cytotoxic chemotherapy, or radiotherapy within 28 days prior to entering the study, or who have not recovered from AEs dur to agents administered more than 28 days earlier.
- •Subjects who are less than 21 days from surgery or have insufficient recovery from surgical-related trauma or wound healing.
- •Prior history of allogeneic hematopoietic stem cell transplantation.
- •Current use of granulocyte colony-stimulating factory (G-CSF) or GM-CSF.
- •History of major organ autoimmune disease.
- •Concurrent immunosuppressive therapy. A stable dose of prednisone \<10 mg daily or inhaled corticosteroids are allowed.
- •Any form of primary immunodeficiency.
- •Active bacillus tuberculosis (TB) or any other active or uncontrolled infection.
- •Pior history of treated malignancy in the past 2 years. Subjects with non-melanoma skin cancer, localized prostate cancer, and carcinoma in situ of the breast of cervix are allowed.
Outcomes
Primary Outcomes
Acute and subacute toxicities and AEs
Time Frame: baseline to four weeks after infusion
The incidence of dose limiting toxicities (DLTs) after PACTN infusion will be used to determine the maximum tolerated dose (MTD). Adverse effects (AEs) and in particular cytokine release syndrome (CRS) and potential autoimmune AEs will be monitored.
Secondary Outcomes
- Overall and progression-free survival of subjects who receive PACTN(Six and 12 months after PACTN infusion)
- Disease Response(Samples will be collected between day 29 and 43, and then at 3, 6, and 12 months)
- Persistence, abundance, and activity of PACTN(Samples will be collected on days 1, 4, 8, 15, 36, and 57, and then 3, 6, and 12 months)